Abeona (ABEO) Enterprise Value to EBITDA Ratio

Abeona Therapeutics (ABEO) operates a non-cyclical business, as the demand for treating orphan diseases is not subject to economic fluctuations. The company is currently scaling its first skin gene therapy, establishing a distribution network and refining delivery processes. These operations rely on external logistics and testing contractors. The share price history, with an EV/EBITDA metric at 0.00, clearly demonstrates the current market valuation of the business.

Abeona Therapeutics Inc. - ABEO Company Value to EBITDA (period 11/23/2025 - 11/14/2026)

Comprehensive metric breakdowns and analytics for abeonatherapeutics.com (ABEO)

- current price and projected stock value:

Stock Price Abeona Therapeutics Inc.|ABEO - Analyst Median Target

- market capitalization details:

Market Valuation Abeona Therapeutics Inc.|ABEO - Full Business Value

- business book valuation details:

Book Value per Share Abeona Therapeutics|ABEO - Total Stockholders' Equity|Market Capitalization to Book Value Ratio abeonatherapeutics.com|ABEO - Total Business Assets

- debt burden and liquidity indicators:

Total Debt to Equity Ratio Abeona Therapeutics|ABEO - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Abeona Therapeutics Inc.|ABEO - Company Aggregate Indebtedness|Debts to Book Capitalization Abeona Therapeutics Inc.|ABEO - Company Long-Term Loans and Borrowings|Company Short-Term Debts Abeona Therapeutics|Quick Liquidity abeonatherapeutics.com

- financial results and valuation multiples details:

ABEO - Final Profit|Expected Profit Abeona Therapeutics|ABEO - Price to Earnings Ratio|Forward P/E Multiple Abeona Therapeutics Inc.|ABEO - PEG Multiple|EV/EBITDA Multiple Abeona Therapeutics Inc.|ABEO - Operating profit EBITDA|Net earnings per share (EPS TTM) Abeona Therapeutics|ABEO - Earnings per share for the last twelve months|Quarterly EPS earnings growth abeonatherapeutics.com|ABEO - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Abeona Therapeutics

- revenue and sales details:

ABEO - Company Total Revenue|Company Projected Revenue Abeona Therapeutics Inc.|ABEO - Market Cap to Revenue Ratio|Forward P/S Multiple Abeona Therapeutics Inc.

Fundamental valuation:Abeona ABEO

Manufactured products of Abeona Therapeutics Inc.

To minimize risks when analyzing capital-intensive companies, it is essential to accurately correlate business value with operational efficiency. This ratio compares the Enterprise Value (EV), including debt, to earnings before interest, taxes, depreciation, and amortization (EBITDA). The EV/EBITDA multiple on a time chart allows for tracking the deviation of market valuation from fundamental indicators. For Abeona Therapeutics (ABEO), this is critical, as exclusive FDA orphan drug rights ensure a stable cash flow protected from price competition.

Key competitors

EV/EBITDA Multiple VRTX (Vertex Pharmaceuticals Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam Corp (ALNY)|INSM: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio UTHR|BMRN: EV/EBITDA Multiple|Company Value to EBITDA BridgeBio Pharma (BBIO)|BGM (BGM Group Limited) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation COGT (Cogent Corp)|Enterprise Value to EBITDA Ratio XERS (Xeris Biopharma)|KROS (kerostx.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arcturus Therapeutics Holdings Inc. ARCT|ETON (Eton Pharmaceuticals Inc) - Company Value to Operating Income Before Depreciation Ratio|Kamada Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation FULC (Fulcrum Corp)|MREO: EV/EBITDA Multiple|protalix.com (PLX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pliant Therapeutics Inc|APLT: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rein Therapeutics, Inc. (RNTX)|Enterprise Value to EBITDA Ratio gelteq.com GELS|EV/EBITDA Multiple AYTU (Aytu BioPharma)|EV/EBITDA Multiple Chemomab Therapeutics Ltd CMMB|SRx Health - EV/EBITDA Multiple|PLRZ - EV/EBITDA Multiple|AEZS: EV/EBITDA Multiple|CYTH (Cyclo Therapeutics, Inc) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|INZY (Inozyme Pharma Inc.) - EV/EBITDA Multiple|Company Value to EBITDA reneopharma.com RPHM|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization COSCIENS Biopharma (CSCI)